Gender Gaps Found in Timing of RA Treatment Initiation
METHODOLOGY:
Researchers conducted a multicenter observational study using data from a Spanish registry to assess gender differences in clinical characteristics and in the timing of b/tsDMARD initiation in patients with RA.
They included 3384 patients with RA (78.1% women) who started their first b/tsDMARD between January 2000 and October 2023.
The main outcomes included the time from RA diagnosis to initiation of the first b/tsDMARD and disease activity at treatment initiation, which were compared by sex.
The analysis stratified treatment initiation periods according to the emergence and marketing of different drugs during the study: Up to December 2006, January 2007-December 2016, and after January 2017.
TAKEAWAY:
Women had a lower mean age at treatment initiation than men (54.8 vs 57.0 years; P < .001) but a longer disease duration (mean, 7.3 vs 6.7 years; P = .031).
< .001) but a longer disease duration (mean, 7.3 vs 6.7 years; = .031). Men had a higher body mass index and more comorbidities, whereas women were more likely to have Sjögren syndrome and osteoporosis.
At treatment initiation, women had a higher Disease Activity Score 28–Erythrocyte Sedimentation Rate than men; however, no difference was observed in Disease Activity Score 28–C-reactive protein.
Gender differences in disease duration before treatment initiation were especially notable in women from 2017 onward (hazard ratio, 0.9; P = .026). A longer RA duration before treatment was observed in women, older patients, and those on other conventional synthetic DMARDs (excluding methotrexate), whereas smokers, individuals with obesity, and those receiving methotrexate or glucocorticoids began treatment earlier.
IN PRACTICE:
"The delay in treatment initiation in women despite a higher activity rate merits reflection," the authors of the study wrote.
SOURCE:
This study was led by Paloma Vela-Casasempere, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain. It was published online on May 14, 2025, in Arthritis Research & Therapy .
LIMITATIONS:
Only the covariates available in the registry were included in this study, potentially missing other confounding factors. Sex was recorded as a dichotomous variable (male/female), without accounting for self-identified gender.
DISCLOSURES:
The registry was supported by the Spanish Agency of Drugs and Medical Devices, Biogen, Bristol-Myers and Squibb, and others. Several authors reported receiving grants or contracts, consulting fees, honoraria, or travel support from various pharmaceutical companies, including Novartis and Pfizer.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Life might have come from outer space, scientist say
The seeds of life on Earth might have come from outer space – and might be widespread throughout the rest of the universe, scientist say. Researchers have found complex organic molecules in a disc around a 'protostar' in a major breakthrough. Those molecules are seen as the precursors to the building blocks of life, which go on to become sugars and amino acids that are then combined into the complex flora and fauna that surrounds us. Researchers have found such complex organic molecules in other places before. But the new findings fill in a previously mysterious missing link – one that could suggest that life is more abundant than we realise. When cold protostar becomes a young star, surrounded by a disc of dust and gas, it is a violent process that includes intense radiation and the hurling out of gas. Researchers had been concerned that the extreme nature of that process could 'reset' the chemical compounds available around a star, meaning that they would have to be formed in the discs that at the same time are making planets. But the new findings suggest that complex molecules can stick around through that process, meaning they will be inherited by the discs that follow. The findings are reported in a new study, 'A deep search for Complex Organic Molecules toward the protoplanetary disk of V883 Ori', published in the The Astrophysical Journal Letters.
Yahoo
23 minutes ago
- Yahoo
Janssen's Darzalex new indication gains EC approval for SMM
The European Commission (EC) has approved the Johnson & Johnson company Janssen-Cilag International's new indication for Darzalex Faspro (daratumumab) subcutaneous (SC) formulation to treat adults with smouldering multiple myeloma (SMM) at high-risk of developing MM. Daratumumab is co-formulated with Halozyme's drug delivery technology, Enhanze. The EC approval is based on outcomes from the Phase III AQUILA study, which assessed the safety and efficacy of fixed-duration daratumumab SC administration against active monitoring in patients with high-risk SMM. The primary endpoint of the study is progression-free survival, while secondary endpoints encompass overall response rate, time to progression and overall survival. Patients included in the study had been diagnosed with SMM within the previous five years. Those with prior exposure to either approved or investigational treatments for SMM or multiple myeloma were excluded from participation. Halozyme president and CEO Dr Helen Torley stated: "This approval reinforces DARZALEX Faspro with ENHANZE as a foundational treatment across all stages of multiple myeloma. "We are pleased that the new treatment paradigm addresses the critical needs of people living with this complex blood disease." Halozyme's Enhanze drug delivery technology, featuring the enzyme rHuPH20, enables rapid SC delivery of drugs and fluids, enhancing patient experience and reducing treatment burden. It has been licensed to companies including Takeda, Roche, Pfizer, AbbVie and Acumen Pharmaceuticals. Johnson & Johnson innovative medicine multiple myeloma disease area leader and vice-president Jordan Schecter stated: 'Until now, there have been no approved treatment options for patients diagnosed with high-risk smouldering multiple myeloma. 'We can now offer physicians and patients the option to treat with daratumumab earlier, significantly delaying progression and the need for more intensive, continuous therapy, as well as extending overall survival.' "Janssen's Darzalex new indication gains EC approval for SMM" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Study Says That 'Micro-Walks' May Be More Effective Than Longer Ones—Even For Weight Loss
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." For years, doctors have stressed the importance of being active during your day—after all, research has found that sitting for too long raises your risk of a slew of serious health conditions, including cardiovascular disease and type 2 diabetes. But the idea of going for hour-long walks can be overwhelming. Now, new research suggests you don't need to jam in a massive stroll into each day: Instead, you can go for 'micro-walks.' That's the main takeaway from a study published in Proceedings of the Royal Society B, which found that micro-walks may be even better for you than long ones. Here's the deal. Interested in making walks part of your regular fitness routine? Check out the exclusive WH+ 4-Week Walking Plan that burns fat and builds muscle at the same time. What are 'micro-walks'? In this study, a 'micro-walk' is defined as walking between 10 and 30 seconds at a time (with breaks in between your next walk). Are 'micro-walks' more beneficial for your health? Why? It depends on how you're looking at it. In this particular study, volunteers walked on a treadmill or climbed a short flight of stairs for different periods of time, ranging from 10 seconds to four minutes. The study participants wore masks to measure their oxygen intake (which can be used to calculate energy or calorie consumption). The researchers discovered that people who walked in short bursts used up to 60 per cent more energy than longer ones, despite the walks covering the same distance. (The more energy you expend, the more calories you can burn.) Basically, you may be able to rev up your metabolism and burn more calories if you do short bursts of walking versus longer cruises around. Albert Matheny, RD, CSCS, a co-founder of SoHo Strength Lab, says there's something to this. 'Getting activity throughout the day, in general, is better for people,' he says. 'It's better for circulation, mental health, and digestive health.' You're also more likely to have a faster pace when you do shorter bursts of walking than if you're going on, say, a five-mile walk, he points out. How many steps should I get per day? This is debatable, and research has shown that the often-quoted 10,000 steps a day may not be necessary. Instead, 7,500 steps or so is ideal—but everyone is different. If you've already been walking, Matheny says that aiming for 10,000 steps a day is great. But if not or if you don't have many opportunities to walk during your day, 7,500 steps may be a better goal. 'It's really about doing what you can,' he says. 'If you're not a big walker and you think, 'I don't want to walk five miles,' then just do 30-second bursts. It's more attainable.'DMX Comfort+ Sneaker $108.49 at 26 $109.95 at 2 $240.00 at You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
